MapperHealth, LLC — SEC Form D Filing

MapperHealth, LLC filed an SEC Form D on May 15, 2026, reporting $8.20M raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
May 15, 2026
Amount reported
$8.20M
Round stage
Seed
Industry
Health Technology
Website
https://www.rxmapper.com/

What the company does

Securities: SAFE. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Current medications may not be effective or safe for all individuals due to genetic differences, which can lead to poor health outcomes. Patients struggle with ineffective treatments, high costs, and complex medication regimens.

Solution

RxMapper provides personalized medication recommendations by analyzing a patient's DNA to determine which drugs are likely to be safe and effective for them. This platform offers telehealth consults and is designed to improve health outcomes and reduce costs.

Why now

The increasing demand for personalized medicine and more effective treatment options make this an ideal time for RxMapper's services.

Verdict

Investors backed MapperHealth because the narrative presented a timely demand for personalized medicine amidst a growing health crisis, not because the competitive landscape seemed entirely favorable. They were implicitly betting on the inevitability of DNA-driven healthcare advancements gaining traction with health plan administrators. The limited upside lies in execution risk given the crowded market with established players like 23andMe, implying that unique differentiation is crucial for long-term sustainability.

Source: SEC EDGAR Form D filing